News
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the Best Large Cap Value Stocks to Invest In. Analyst Courtney Breen of ...
Gilead Sciences (GILD) stock slips as the company agrees to pay $202M to settle allegations that its HIV drug promotion ...
StockStory.org on MSN10h
Q1 Earnings Roundup: Gilead Sciences (NASDAQ:GILD) And The Rest Of The Therapeutics SegmentAs the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...
9h
Gulf Business on MSNGilead’s Vítor Papão on key partnerships and the role of tech in public healthGilead's Papao shares insights on the evolving role of public-private collaboration in healthcare, and how emerging tech is ...
A landmark breakthrough in HIV prevention — a scientific feat decades in the making — received final approval from the Food ...
Massachusetts AG Campbell secures $1.6 million for the state's Medicaid in a settlement with Gilead over illegal kickbacks ...
LOS ANGELES, July 16, 2025 /PRNewswire/ — The Schall Law Firm, a national shareholder rights litigation firm, announces that ...
"Government health care dollars are precious and must be used without favor in order to achieve the highest possible health ...
Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...
The country isn’t getting extra money from the Global Fund to Fight Aids, TB and Malaria; it has to use cash from a grant it ...
21h
AllAfrica on MSNSouth Africa Gets R520 Million to Buy the Twice-a-Year Anti-HIV Jab - But There's a SnagSA has accepted an offer of just over R520-million from the Global Fund to Fight Aids, TB and Malaria to buy the twice-a-year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results